<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293202</url>
  </required_header>
  <id_info>
    <org_study_id>200311904</org_study_id>
    <nct_id>NCT00293202</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients</brief_title>
  <official_title>The Effect of Etanercept in Suppression of the Systemic Inflammatory Response in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaysen, George A., M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaysen, George A., M.D., Ph.D.</source>
  <brief_summary>
    <textblock>
      Etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid&#xD;
      arthritis. We are examining whether Etanercept is effective in improving the nutritional&#xD;
      status of hemodialysis patients as a consequence of its ability to decrease inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients with end stage renal disease have a high mortality rate. In individual&#xD;
      patients, mortality is associated with a low serum albumin concentration, a marker of poor&#xD;
      nutritional status, and with elevated C-reactive protein, a marker of inflammation. Since&#xD;
      efforts to improve nutrition through dietary intake have not been successful, inflammation is&#xD;
      thought to play a key role in determining nutritional status. Recently, it has been shown&#xD;
      that malnutrition, inflammation, and atherosclerosis are closely related in patients with&#xD;
      chronic renal failure. It is our hypothesis that suppression of the cycle of inflammation,&#xD;
      malnutrition, and vascular injury caused by atherosclerosis will improve survival in dialysis&#xD;
      patients. This study is designed to examine whether suppression of the inflammatory response&#xD;
      can be accomplished safely with Etanercept and to determine if this suppression will improve&#xD;
      nutritional status and clinical outcome in hemodialysis patients with poor nutritional status&#xD;
      and evidence of inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We were unable to recruit sufficient patients within the confines of our budget considering the&#xD;
    restrains on our recruitment criteria&#xD;
  </why_stopped>
  <start_date type="Actual">January 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blind study- one group received 25mg Etanercept twice per week; the other is control - receiving saline twice per week</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind Study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>52 weeks</time_frame>
    <description>An increased serum albumin (ALB) concentration expected. Higher concentrations of Albumin indicate better outcome. Normal ranges of Albumin in this study is from 3.5 to 5.5 gram per deciliter (g/dL). We expect ALB to remain or increase in this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>52 weeks</time_frame>
    <description>A reduced C-reactive protein (CRP) concentration is expected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prealbumin (mg/dL)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Effect of treatment on prealbumin (PAB) concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Etanercept 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept 25 mg injection twice a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection twice a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week</description>
    <arm_group_label>Etanercept 25 mg</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hemodialysis patients will receive Saline by subcutaneous injection twice a week</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of end stage renal disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within&#xD;
             previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus&#xD;
             erythematosis, presence of transcutaneous access (external catheter)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Kaysen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis, Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/20497755/</url>
    <description>B.R. Don, K.Kim, J. Li, T. Dwyer, F. Alexander and G.A. Kaysen.The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. 2010; 73: 431-438. doi: 10.5414/CNP73431</description>
  </link>
  <results_reference>
    <citation>Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol. 2010 Jun;73(6):431-8.</citation>
    <PMID>20497755</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>February 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <results_first_submitted>February 25, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaysen, George A., M.D., Ph.D.</investigator_affiliation>
    <investigator_full_name>George A. Kaysen, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>etanercept</keyword>
  <keyword>malnutrition</keyword>
  <keyword>inflammation</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT00293202/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The protocol was approved by the Human Subjects Review Committee of the University of California Davis Medical Center and Dialysis Clinics, Incorporated. Screening started in January 2005, and had to be terminated early due to low enrollment in December 2006</recruitment_details>
      <pre_assignment_details>Subject was consented and screened for safety. Then they have to qualify for 3 monthly screening values. Once deemed qualified for the study, subject then randomized into a double-blind study; to follow regimen of protocols and followed to 52 weeks of study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Active Comparator: Etanercept 25 mg injection twice a week&#xD;
5 Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week&#xD;
Do not have active infections&#xD;
Patient will be followed for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo comparator: Saline injection twice a week&#xD;
5 Hemodialysis patients will receive Saline by subcutaneous injection twice a week&#xD;
Do not have active infections&#xD;
Patient will be followed for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive ANA (antinuclear antibody)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>on-hold due to fistula maturation time</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total number of participant in each group</population>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>Etanercept 25 mg injection twice a week&#xD;
Etanercept: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline injection twice a week&#xD;
Placebo: Hemodialysis patients will receive Saline by subcutaneous injection twice a week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="16.739"/>
                    <measurement group_id="B2" value="55" spread="15.209"/>
                    <measurement group_id="B3" value="53" spread="15.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <description>C-Reactive Protein is serum protein measured in milligram per liter (mg/L). Increase number indicate higher level of inflammation</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.05" spread="15.60"/>
                    <measurement group_id="B2" value="10.98" spread="3.95"/>
                    <measurement group_id="B3" value="15.79" spread="28.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <description>Serum Albumin is measured in gram per deciliter (g/dL). Increase number is a measured of better nutritional status</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.39" spread="0.24"/>
                    <measurement group_id="B2" value="3.31" spread="0.21"/>
                    <measurement group_id="B3" value="3.37" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Albumin</title>
        <description>An increased serum albumin (ALB) concentration expected. Higher concentrations of Albumin indicate better outcome. Normal ranges of Albumin in this study is from 3.5 to 5.5 gram per deciliter (g/dL). We expect ALB to remain or increase in this study.</description>
        <time_frame>52 weeks</time_frame>
        <population>Hemodialysis patients have a high mortality rate caused by poor nutrition and inflammation. The hypothesis is that suppression of inflammation reverses the malnutrition-inflammation syndrome in hemodialysis patients. Etanercept is an anti-inflammatory agent. Thus it is expected that participant given Etanercept will have a reduced amount of inflammation in their bodies and have better nutritional status - indicated by an increase/steady Albumin level.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Active comparator: Etanercept 25 mg injection twice a week&#xD;
Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week for a total of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>No Drug: Saline injection twice a week&#xD;
Hemodialysis patients will receive Saline by subcutaneous injection twice a week for a total of 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin</title>
          <description>An increased serum albumin (ALB) concentration expected. Higher concentrations of Albumin indicate better outcome. Normal ranges of Albumin in this study is from 3.5 to 5.5 gram per deciliter (g/dL). We expect ALB to remain or increase in this study.</description>
          <population>Hemodialysis patients have a high mortality rate caused by poor nutrition and inflammation. The hypothesis is that suppression of inflammation reverses the malnutrition-inflammation syndrome in hemodialysis patients. Etanercept is an anti-inflammatory agent. Thus it is expected that participant given Etanercept will have a reduced amount of inflammation in their bodies and have better nutritional status - indicated by an increase/steady Albumin level.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.22"/>
                    <measurement group_id="O2" value="3.42" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein</title>
        <description>A reduced C-reactive protein (CRP) concentration is expected.</description>
        <time_frame>52 weeks</time_frame>
        <population>Malnutrition, inflammation, and atherosclerosis affect patients with chronic renal failure. High C-reactive protein is a marker of inflammation. This study is designed to examine whether suppression of the inflammatory response can be accomplished safely with Etanercept. For those who has high CRP level, we expect that CRP level will be reduced</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Active comparator: Etanercept 25 mg injection twice a week&#xD;
Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>No Drug - Saline injection twice a week&#xD;
Hemodialysis patients will receive Saline by subcutaneous injection twice a week for a total of 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein</title>
          <description>A reduced C-reactive protein (CRP) concentration is expected.</description>
          <population>Malnutrition, inflammation, and atherosclerosis affect patients with chronic renal failure. High C-reactive protein is a marker of inflammation. This study is designed to examine whether suppression of the inflammatory response can be accomplished safely with Etanercept. For those who has high CRP level, we expect that CRP level will be reduced</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.96" spread="26.00"/>
                    <measurement group_id="O2" value="11.94" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prealbumin (mg/dL)</title>
        <description>Effect of treatment on prealbumin (PAB) concentration</description>
        <time_frame>52 weeks</time_frame>
        <population>Serum Prealbumin is measured in milligram per deciliter (mg/dL). Increase number is a measured of better nutritional status.&#xD;
In the etanercept group we would expect fewer decreases in prealbumin. Decreased level of prealbumin may indicate inflammations may be occurring in the body.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 25 mg</title>
            <description>Etanercept 25 mg injection twice a week&#xD;
Etanercept: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Saline injection twice a week&#xD;
Placebo: Hemodialysis patients will receive Saline by subcutaneous injection twice a week</description>
          </group>
        </group_list>
        <measure>
          <title>Prealbumin (mg/dL)</title>
          <description>Effect of treatment on prealbumin (PAB) concentration</description>
          <population>Serum Prealbumin is measured in milligram per deciliter (mg/dL). Increase number is a measured of better nutritional status.&#xD;
In the etanercept group we would expect fewer decreases in prealbumin. Decreased level of prealbumin may indicate inflammations may be occurring in the body.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.36" spread="8.64"/>
                    <measurement group_id="O2" value="31.43" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Adverse Event collected was in the same category as defined</desc>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>Etanercept 25 mg injection twice a week&#xD;
Etanercept: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline injection twice a week&#xD;
Placebo: Hemodialysis patients will receive Saline by subcutaneous injection twice a week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CABG</sub_title>
                <description>Coronary artery disease syndrome resulting in 3-vessel CABG&#xD;
- not related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <description>Ventricular fibrillation during elective cardiac catheterization for kidney transplant evaluation&#xD;
- Not related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Epigastric pain</sub_title>
                <description>Nausea, vomiting, constipation, and epigastric pain initially thought to be pancreatitis, but later found to be either gastroenteritis or peptic ulcer disease&#xD;
-Not related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Stroke, considered related to elective catheterization to evaluate for kidney transplant, due to development of memory loss and left leg weakness (following ventricular fibrillation during catheterization)&#xD;
-not related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <description>Fever, cough, chest congestion&#xD;
-Unlikely related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hematuria, chest pain, nausea and vomiting</sub_title>
                <description>Hematuria, chest pain, nausea and vomiting&#xD;
- Not related to Study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Skin pain</sub_title>
                <description>Burning pain in hands&#xD;
-Not related to Study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 10 out of 40 subjects recruited. Only 5 out of 10 subject randomized completed the study. The study has been slow to accrue patients due to the large number and stringent inclusion and exclusion criteria so as to optimize safety. This is due to Etanercept as an anti-inflammatory agent that acts directly on a key regulatory protein in the immune system, tumor necrosis factor α. Extreme stringency was intended to prevent the potential unmasking of latent infection.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>George Kaysen MD PhD</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-3774</phone>
      <email>gakaysen@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

